Contribution of Institut Pasteur &
Institut Pasteur International Network
in
Global Research Collaboration
for Infectious Disease Preparadeness
Noël TORDO (Paris) & Ralf ALTMEYER (Shanghai)
Louis Pasteur vision : « improve human health and
welfare through scientific discovery »
1887
2013
François JACOB Center
A multidisciplinary research center
dedicated to emerging diseases
Institut Pasteur :
a private non profit foundation of public utility
•
3 missions:
•
Biomedical Research
•
Public Health: monitoring infectious disease, expertise, field interventions
•
Sharing knowledge: teaching and training
• 2400 scientists, technicians, Public Health
•
(> 60 nationalities)
10 Departments, 130 Research Units (half-dedicated to infectious diseases)
Viral diseases
Flu, hepatitis, dengue, SARS, Chikungunya, AIDS, rabies,
poliomyelitis, yellow fever, hemorrhagic fevers
Bacterial diseases
Meningitis, tuberculosis, enteric diseases, plague, whooping
cough, anthrax
Parasitic diseases
Malaria, leishmaniasis, amibiasis, Chagas disease, sleeping
sickness
Fungal diseases
Cryptococcosis, candidiasis, aspergillosis
Institut Pasteur : in the top 10 of Institutions for
« Neglected Disease Research & Developement »
2012 budget :
270.5 M €
Public Funds
23.0 %
Donations
& Legacies
27.8 %
47.6 %
Business Development :
Fees, royalties, expertise,
Research grants
Institut Pasteur :
infrastructure in Paris, field intervention
•
Platforms in Paris:
•
High security laboratories (BSL3, A3)
•
High-throughput technology (genomics, proteomics, imaging, insectarium)
•
Biological ressources (collections of pathogens, biobanking)
• LabEx IBEID (Integrative Biology of Emerging Infectious Diseases)
• To strengthen preparedness by increasing knowledge and expertise in basic
microbiology and microbial immunology.
• To establish a continuum of research between surveillance, detection and
basic analysis of the etiological agent and infected host
• To explore microbial diversity, host complexity, host-microbe interactions, to
find novel targets for vaccinology and therapeutics
• 45 academic teams (in & out Pasteur), 5 Public Health Partners (Hospitals,
Vet School, ANSES, InVS), 3 industry partners (Sanofi-BioMérieux-Danone)
•
CIBU (Laboratory for Urgent Response to Biological Threats)
• Capacity building
• Field investigations
Public Health : WHO Collaborative Centers, OIE
Reference Lab & National Reference Centers
Research units <-> Surveillance centers for infectious diseases

•
•
•

15 National Reference Centers (Paris)
Bacteria : Anaerobic & botulism; Corynebacteria diphtheriae complex; E. coli, Shigella,
Salmonella; Leptospirosis; Listeriosis; Meningitis; Plague & other Yersinia, Vibrios and cholera;
whooping cough
Viruses : Hantavirus; Hemorrhagic fevers; Influenza; Papillomavirus; Rabies
Fungi : Invasive fungal infections and antifungal
4 Associated References Laboratories (French Guiana)
Arboviruses, Hantavirus, Influenza, Malaria

8 WHO Collaborating Centers (Paris)
•
Bacteria : Leptospirosis; Listeria; Meningococcus ; Plague & other Yersinia Infections;
•
Salmonella
Viruses: Arboviruses & Viral Hemorrhagic Fevers; Enteroviruses (poliovirus vaccine) ;
Rabies
 1 OIE Reference Laboratory (Paris)
• Rift Valley Fever & Crimean Congo Hemorrhagic Fever
GOARN
One Health
Teaching and training at the Institut Pasteur
Teaching Centre in Paris / year
- 25 Specialized Courses (Virology, Bacteriology, Zoonoses, Epidemiology,
Immunology, Genomic, Neurobiology…)
- 500 attendees: Master, PhD, Post-Doc, Scientists, Med/Vet ( > 60 countries)
- 500 lecturers (Europe)
Training in Paris / year
- 80 Master students
- 220 PhD students (PhD International program)
- > 250 Post-Doc
Teaching in the Institut Pasteur Network / year
- 25 Regular Courses : Virology, Cell Biology, Immunology (Hong-Kong) Encephalitis
-
(Cambodia); Malaria (Madagascar), Bioinformatics, Salmonella (WHO)
15 Specific Courses: Basic Research to Public Health (50% with external funding,
partnership with Health Autorities & Universities)
24 Proposals for 2014: Africa 10, Americas 6, Asia-Pacific 4, Europe 1, MATI 2
Institut Pasteur :
European and International partnerships
Europe, FP7
Others (IP-Network)
US-DHHS (Cambodia, Cameroon, CAR,
Senegal) IHR & viral respiratory infections
GEIS (Laos) Tick borne diseases
NIH (Cambodia) Camelia project HIV-TB
US CDC
USAID : (Madagascar, Cameroon, Ivory
Coast) malaria, zoonosis, nutrition
PEPFAR HIV (Ivory Coast)
building laboratory capacity for HIV
AFD ECOMORE
JICA-JST (Laos)
WHO – IHR Global Health To assist
countries in strengthening their capacity for
surveillance, detection, and response
Institut Pasteur International Network :
A global Network with 32 Institutes / 25 countries / 5 continents
One network, multiple international programs on ID
Europe
Medit.
Americas
Asia
Pacific
Regions
BSL3
Sub-saharan Africa
Network programs (selection)
 PAANTHER
: Clinical and immunological aspects of Paradoxical Tuberculosisassociated Immune Reconstitution Inflammatory Syndrome in HIV-TB co-infected children
Cambodia, Vietnam, Burkina fasso, Cameroon; Sponsor: ANRS 12279
 DENFREE : Dengue research Framework for Resisting Epidemics in Europe
Cambodia, Thailand, IP Paris, Cuba, Europe; Sponsors: EU
 PREDICT : Expanding national capacity for zoonotic disease surveillance
Asia, Africa, USA; Sponsor: USAID
 Core capacities for Influenza preparedness (2005) [IHR 2005]
Cambodia, Cameroon, Central African Republic, Senegal, Sponsor: DHHS
 AGISAR : An integrated surveillance study of antimicrobial resistance in Salmonella
subspecies, Campylobacter spp, Escherichia coli and Enterococcus spp from foodproducing animals, retail meat and outpatients
National Pediatric Hospital, Phnom Penh, Cambodia; Sponsor: WHO/FAO
Set up of a Mediteranean
Laboratory Network
priorities :
Biosafety,
West Nile and
Dengue
Training Dengue/West Nile & Biosafety in
the lab
02-06 July 2012, IP – 23- 27 June 2013
Madrid
17 trainees + 6 international experts
Networks against tuberculosis
Improve diagnostic of drug
resistant tuberculosis
OPEC, Gabon
10 african countries : Cameroon, Ivory coast,
Central African Republic, Niger, Benin, Burkina
Faso, Gabon, Guinee-Bissau, Mali, Togo
3 european countries : France, Italy, Austria
1 Asian country: China
Outbreak investigation within the Pasteur network
Outbreak investigation: emergence of Enterovirus 71 (2012)
China, Vietnam and recently Cambodia
CNS infections & deaths in young children (JCV 2012, EMI 2013)
- 2010 (China): 1.7m cases, 27,000 severe, 900+ deaths
Task force: IP Cambodia, Shanghai, Paris, HKU
1st cases in April 2012 but confirmation (after testing for >40
pathogens) in June 2012
- funded by IP Paris, Li Ka Shing Foundation, IPS, IPC
EV71 C4 genotype identified: Close phylogenetic relationship
with China & Vientam strains (Promed SEP 2012)
Factors of severe disease, drug repurposing
14  Marc Jouan • IP-RIIP  04/10/13
Approved drug repurposing for EID
Suramin inhibits EV71 in vitro and in vivo
CTRL
Suramin
EV71, WT virus
Neonate mouse model
Viral Load (copies/ml)
EV71 WT virus,
Adult monkey model
MW: 1429.17
Treatment, Infection
Days post infection
Suramin inhibits recently circulating EV71 strains from China and Cambodia
Suramin approval status (AT): Treatment & prophylaxis in children and infants
Selected as clinical candidate based on efficacy, PK and safety data
Ren et al, submitted
спасибо
Merci
Thanks
Merci
Merci
‫شكرا‬
谢谢
cảm ơn bạn
¡gracias
благодаря